#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis rapidly progressive Fibrosarcoma Peripheral T-cell lymphoma unspecified Chondrosarcoma metastatic Medulloblastoma recurrent Follicle centre lymphoma follicular grade I, II – III Iron overload Heavy menstrual bleeding Congenital hypotransferrinaemia Anaplastic large cell lymphoma T- and null-cell types Sickle cell disease Squamous cell carcinoma of the cervix Familial haemophagocytic lymphohistiocytosis Retinoblastoma Glioblastoma More trials…

    Learn about Rare Diseases

    Primary biliary cholangitis – Treatment Mastocytosis – Life with Disease Synovial sarcoma metastatic Pituitary-dependent Cushing’s syndrome – Diagnostics Niemann-Pick disease – Treatment Inclusion body myositis Leiomyosarcoma recurrent – Basic Information Stevens-Johnson syndrome – Diagnostics Ornithine transcarbamoylase deficiency – Diagnostics Synovial sarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Isoprenaline Hydrochloride Crovalimab Amniotic Membrane, Human Nitric Oxide POLYSORBATE 80 Pelareorep Mavorixafor Lib-01 Monohydrate SGN-ALPV Bepranemab Lauromacrogol 400 Nirogacestat Hydrobromide Vusolimogene Oderparepvec Axicabtagene Ciloleucel 534 D5-Ethyl-Beta-D-Glucuronide Mifamurtide Heparin Calcium Retifanlimab MALIC ACID More therapies…

    Learn about Your Condition

    Pathogen resistance Endometrial cancer stage III Elderly Renal impairment Corticobasal degeneration Metastases to biliary tract B-cell lymphoma recurrent Viral myocarditis Death neonatal CDKL5 deficiency disorder Anxiety disorder Vaginal haemorrhage Head and neck cancer stage III Hand dermatitis Lumbosacral radiculopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Specjalistyczny Gabinet Dermatologiczno- Kosmetyczny…

Specjalistyczny Gabinet Dermatologiczno- Kosmetyczny

Borkowska 29A/9, Cracow, 30-438, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Deucravacitinib for Children with Moderate to Severe Plaque Psoriasis

    Recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    France Germany Poland Romania Spain
  • Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Tildrakizumab
    Bulgaria Hungary Poland
  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    • Apremilast
    Austria Estonia France Germany Hungary Latvia +3

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!